Q-omics provides the consensus-scored NPLOC4 profile across patient tissues and cancer cell-line models. NPLOC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NPLOC4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NPLOC4 protein abundance shows 20,772 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, HNSC, and PDAC as cancer lineages where NPLOC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPLOC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPLOC4 survival associations across molecular data types. NPLOC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPLOC4 RNA expression–survival associations across cancer types. High NPLOC4 expression shows unfavorable associations in LIHC, ACC, MESO, KIRC, LGG and UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NPLOC4 RNA expression.
This table summarizes NPLOC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NPLOC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPLOC4 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, LUAD and KIRP. The HNSC box plot shows higher NPLOC4 RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with NPLOC4 in patient tissues and cancer cell lines. In patient samples, NPLOC4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NPLOC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
